Chromocell Therapeutics Profit Margin

Chromocell Therapeutics's profit margin stands at -165.24% as of June 2026. That is below the sector sector average of 21.44%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Chromocell Therapeutics sits lower the its sector benchmark (21.44%) with a profit margin of -165.24%. That is roughly 870.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -165.24% for Chromocell Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Chromocell Therapeutics's profit margin evolved across reporting periods, while the comparison chart places CHRO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.